Diplomat Releases 2014 Satisfaction Survey Results
FLINT, Mich. – May 15, 2015 – The nation’s largest independent specialty pharmacy announces its 2014 patient satisfaction survey results.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the results from its 2014 patient survey. Every year Diplomat engages an independent third-party agency to evaluate the levels of satisfaction, study the customer’s experience and track its service delivery performance over time.
For 2014, Diplomat received a 99 percent satisfaction rate from patients in all four-survey categories:
- Overall satisfaction
- Telephone courtesy
- Helpfulness of pharmacists
- Helpfulness of patient care staff
The survey found that 95 percent of patients would recommend Diplomat to their family, friends and co-workers.
“The results are inspiring,” said Gary Kadlec, Diplomat president. “It’s crucial to keep a finger on the pulse of the patient experience, and look for ways we can do better. Our company is centered around the patient, and it shows in our continued achievement in patient satisfaction.”
To learn more about Diplomat, visit www.diplomat.is.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Marketing & Public Relations
810.768.9580 | firstname.lastname@example.org
@PharmacDailyRT @PharmacDaily: @DiplomatRx to distribute Puma Biotechnology’s new cancer drug $DPLO https://t.co/gl0v6WURVV4 days ago
@DiplomatRxNerlynx (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting https://t.co/vi3ACWhbfe5 days ago
@AJPB_JournalRT @AJPB_Journal: Be sure to check out our Insights page featuring videos of Cheryl Allen from @DiplomatRx discussing #RA https://t.co/qxZc…2 weeks ago
@DiplomatRxWe're with @340BCoalition this week in Washington D.C.! Come say hello.2 weeks ago
@SpecialtyPTimesRT @SpecialtyPTimes: Rheumatoid Arthritis Treatment Guidelines https://t.co/sEhe74UozC #rheumatoidarthritis @DiplomatRx3 weeks ago